For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Start JEVTANA with prednisone after a docetaxel-containing regimen to
Offer your mCRPC patients MORE1

MORE Survival1

15.1 months (95% CI: 14.1 - 16.3) median overall survival for patients receiving JEVTANA (n=378) vs 12.7 months (95% CI: 11.6 - 13.7) with mitoxantrone (n=377) (P<0.0001). Number of deaths 234 (62%) with JEVTANA vs 279 (74%) with mitoxantrone.

MORE Tumor Response1

JEVTANA delivered a ≥30% (RECIST Criteria) reduction in tumors in 3X more mCRPC patients vs mitoxantrone, an active comparator: 14.4% (29/201) (95% CI: 9.6 - 19.3) vs 4.4% (9/204) (95% CI: 1.6 - 7.2) (P=0.0005).2,3

Recommended Dosing1

JEVTANA 20 mg/m2 every three weeks + oral prednisone 10 mg daily throughout treatment. 25 mg/m2 can be used in select patients. 

JEVTANA is a NCCN designated Category 1 second-line therapy for mCRPC.4



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are leaving

You are leaving to view another Sanofi Genzyme Corporation website.

Continue Cancel